Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington’s Disease (HD)

              Author:Kumar, Rajeev   Claassen, Daniel   Mongan, Ann   Hoehn, Benjamin   Lin, Ping   Cahir-Mcfarland, Ellen   Guo, Chenying   Volman, Vladislav   Taylor, Lori   Chandra, Priya   Yednock, Ted   Kroon, Henk-Andre   

              Session Name:S32: Movement Disorders: Trials  

              Topic:Movement Disorders  

              Program Number:S32.009  

              Author Institution:Rocky Mountain Movement Disorders Center, Englewood, CO  Vanderbilt University Medical Center, Nashville, TN  Annexon Biosciences, South San Francisco, CA